What are the cardiovascular benefits of sglt-2 inhibitors compared to glp-1 analogues?

Question

Accepted Answer

SGLT-2 inhibitors (SGLT-2i) and GLP-1 receptor agonists (GLP-1RA) provide comparable reductions in major adverse cardiovascular events (MACE), but SGLT-2i demonstrate superior protection against hospitalization for heart failure (HHF) and renal decline, while GLP-1RAs may offer specific advantages regarding stroke and glycemic-dependent risk in patients with preserved renal function.

## Major Adverse Cardiovascular Events (MACE)
SGLT-2i and GLP-1RA classes demonstrate similar overall efficacy in reducing the risk of 3-point MACE (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) in patients with type 2 diabetes (Direct, High; PMID: 35296336, PMID: 37381019).
*   **Relative Risk Reduction:** Network meta-analysis indicates no significant difference between the two classes for total MACE (RR = 0.98, 95% CI 0.91–1.07) (Direct, High; PMID: 35296336). In patients with chronic kidney disease (CKD), SGLT-2i and GLP-1RAs also show comparable risk reduction for MACE-3 (Direct, High; PMID: 33413348).
*   **Absolute Benefit:** GLP-1RAs may provide slightly higher absolute risk reduction (ARR) in younger patients (under 65 years) and those with normal renal function (eGFR ≥ 60 mL/min/1.73 m²), whereas SGLT-2i effects on MACE are more pronounced in patients with reduced eGFR or albuminuria (Direct, High; PMID: 37381019).
*   **Subclass Variability:** Within the GLP-1RA class, human GLP-1 analogues (e.g., liraglutide, semaglutide) significantly reduce MACE-3, whereas exendin-4 analogues (e.g., lixisenatide, exenatide) may not show the same level of cardiovascular benefit (Direct, High; PMID: 33413348).

## Heart Failure and Mortality
SGLT-2 inhibitors provide a robust and superior reduction in hospitalization for heart failure compared to GLP-1RAs (Direct, High; PMID: 35296336).
*   **Hospitalization for Heart Failure (HHF):** SGLT-2i are significantly more effective than GLP-1RAs for reducing HHF (RR = 0.76, 95% CI 0.68–0.85) (Direct, High; PMID: 35296336).
*   **Cardiovascular and All-Cause Mortality:** Both classes reduce cardiovascular and all-cause mortality similarly when compared to placebo or DPP-4 inhibitors (Direct, High; PMID: 35296336, PMID: 37677118). Network meta-analyses found no significant difference in the risk of cardiovascular death between SGLT-2i and GLP-1RAs (Direct, High; PMID: 35296336).

## Renal Outcomes
SGLT-2 inhibitors are superior to GLP-1RAs in preventing composite renal outcomes, such as end-stage renal disease (ESRD) and sustained declines in eGFR (Direct, High; PMID: 35296336, PMID: 33413348).
*   **Comparative Efficacy:** SGLT-2i are associated with a lower risk of renal outcomes compared to GLP-1RAs in both general diabetic populations (RR = 0.78, 95% CI 0.68–0.90) and specifically in CKD cohorts (RR = 0.79, 95% CI 0.63–0.99) (Direct, High; PMID: 35296336, PMID: 33413348).
*   **Mechanisms:** The superior renal protection of SGLT-2i is attributed to improved vascular hemodynamics and reduced intraglomerular pressure through increased sodium delivery to the macula densa (Direct, Medium; PMID: 39994802, PMID: 33413348).

## Combination Therapy vs. Monotherapy
Combining SGLT-2i and GLP-1RAs may provide additive or synergistic cardiovascular benefits by leveraging complementary mechanisms (Derived, Medium; PMID: 39994802).

---

### Unverified Citations

The following sources failed to support their assigned claims after 3 verification rounds designed to ensure only high-confidence, relevant references are retained:

- **PMID:33413348** — *SGLT-2 inhibitors provide a robust and superior reduction in hospitalization for heart failure compared to GLP-1RAs*  
  Failed: conclusion — While the paper finds SGLT-2i superior to GLP-1RAs for renal events, it does not explicitly conclude they are superior for heart failure hospitalization reduction.
- **PMID:33413348** — *This benefit is consistently observed across patients with and without CKD*  
  Failed: disease,conclusion — The study was restricted to patients with CKD (eGFR < 60) and did not include or verify consistency in patients without CKD.